A shadow economy for unapproved weight-loss medications is propelled by social media fitness personalities and sellers on communication apps, based on new investigations.
Experimental Treatment Gaining Traction Via Social Media
Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are encouraged to contact these accounts directly for supplier links, while also receiving discount codes.
Thriving Commerce on Social Networks
Additionally, a robust market exists on messaging services, where communities with thousands of participants share “before and after” images, injection guides and assertions of rapid UK delivery. Vendors market the drug there before directing customers to WhatsApp for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injection created by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies indicate it could help patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Medical Experts Voice Concerns
However, physicians and chemists have cautions that the sale of what remains an unapproved drug in the United Kingdom is worrisome and could lead to users injecting products of unknown origin.
Some experts said the demand for the experimental drug could be connected to the rising cost of licensed slimming products such as Mounjaro.
Regulatory Position and Enforcement
Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that cannot be promoted or supplied for human use under the Human Medicines Regulations 2012.
Some content creators try to sidestep the rules by calling to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and supply can still breach pharmaceutical, advertising, and consumer regulations, potentially leading to fines, legal action or imprisonment.
Service Reaction and Content Removal
According to the social media company, the platform has taken down problematic material and prohibited associated keywords and query recommendations. The company said it was committed to maintaining the platform safe and allocating resources in enhancing enforcement strategies.
Digital Trading Activities
Research also found groups with up to 9,000 participants selling retatrutide using the platform's integrated search feature, which operates like a public directory. Typing “retatrutide” instantly brings up channels with thousands of members, populated with images of slimming results, glowing reviews and step-by-step guides for preparing or administering at home.
Within moments of entering one group, a seller shared contact information, where the majority of transactions take place. The seller provided an instruction manual and guaranteed delivery within 48 hours. When asked whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None asked about weight, health issues or previous experience.
Product Details and Pricing
Within these communities, messages display black plastic parcels with Royal Mail stickers, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, prepared at home with purified liquid, or ready-to-use pens typically sold at £160 for 20mg. When questioned how much time a injector should be used, sellers give conflicting responses varying between a few weeks to “depends on your body”.
Platform Moderation and Safety Measures
A spokesperson for Telegram stated it actively monitored harmful content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are administering materials they cannot confirm. Although the science behind retatrutide is sound, these digital products may not include what they claim,” stated a pharmacy expert, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of an online medical service connected the increase in demand to current cost increases for approved slimming medications such as Mounjaro. “With prices increasing, patients are using online platforms. But counterfeit injections are highly risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she explained.
Her staff has already seen individuals harmed by self-injection from unverified sources. “We understand the frustration, but buying from messaging apps or communication platforms is taking chances with your well-being,” said Wyllie. “These substances could be impure or incorrectly dosed.”
Manufacturer Position
A spokesperson from the pharmaceutical company said retatrutide was in phase 3 clinical trials and had not been reviewed or authorized by any government authority anywhere in the world. “Therefore at this time no one can market [it] for personal consumption,” they said, noting that any item “misleadingly claiming itself as a company investigational substance not yet authorized … may subject users to potentially serious health risks”.